TORONTO, Feb. 13 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. today announced that Vaughn Embro-Pantalony has been appointed to the Board of Directors. He is replacing James A. Long who has assumed his duties as Chief Financial Officer, and has resigned as a director.
“Jim Long has played an important role and assumed many duties as a Director since the inception of the Company and I am delighted to have him on the executive team and bringing his years of experience in financial management to his new key role in the development of our business,” said William. J. Gastle, Chief Executive Officer.
“Vaughn C. Embro-Pantalony is a familiar person in the Company having worked at Microbix in business development and licensing. He is an experienced finance executive having worked with Novopharm Ltd., Bayer Canada Inc., and Zeneca Pharma Ltd. His extensive experience in financial governance, external reporting, audit, tax, financing, product licensing and mergers & acquisitions will strengthen and broaden the knowledge base already in place at Microbix.”
Mr. Embro-Pantalony has a BA in Economics from Wilfred Laurier University, an MBA from the University of Windsor and is a Certified Management Accountant. He has also completed the Executive Program at Princeton University. His consulting practice, the StratPath Group specializes in providing financial solutions to life science companies.
Mr. Gastle went on to say, “Vaughn’s appointment is an ongoing part of the reorganization of the Board and executive team and these changes come at the right time for us to move forward in building our business on the most significant scientific opportunities created by the Company.”
Microbix specializes in developing proprietary biological technologies and commercializing them through global partners. Its products include biotherapeutic drugs, vaccines, and infectious disease diagnostics. Established in 1988, the Company is headquartered in Toronto.
This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to develop and commercialize, resistance to business model for commercialization and implementation; risk associated with operations among others. These forward-looking statements represent the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.
Microbix Biosystems Inc.
CONTACT: visit www.microbix.com or contact: William J. Gastle, Chairmanand CEO, Microbix Biosystems Inc., (416) 234-1624 x 230
